These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 30338457)

  • 1. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
    Hu B; Jacobs R; Ghosh N
    Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
    Merryman RW; Armand P; Wright KT; Rodig SJ
    Blood Adv; 2017 Dec; 1(26):2643-2654. PubMed ID: 29296917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Checkpoint inhibitors in Hodgkin lymphoma].
    Sasse S; Momotow J; Engert A
    Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
    Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
    Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
    Hradska K; Kascak M; Hajek R; Jelinek T
    Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
    [No Abstract]   [Full Text] [Related]  

  • 11. Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
    Sheikh S; Kuruvilla J
    Expert Opin Biol Ther; 2019 Nov; 19(11):1119-1126. PubMed ID: 31456438
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
    Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
    Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
    Lin N; Song Y; Zhu J
    Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.
    De Re V; Caggiari L; Repetto O; Mussolin L; Mascarin M
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31581738
    [No Abstract]   [Full Text] [Related]  

  • 15. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
    Tobin JWD; Bednarska K; Campbell A; Keane C
    Cells; 2021 May; 10(5):. PubMed ID: 34068762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.
    Chang A; Schlafer D; Flowers CR; Allen PB
    Expert Opin Investig Drugs; 2018 Jan; 27(1):55-70. PubMed ID: 29228840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
    Xu-Monette ZY; Zhou J; Young KH
    Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibition in classical hodgkin lymphoma.
    Pezeshki PS; Eskian M; Hamblin MR; Rezaei N
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):1003-1016. PubMed ID: 33857395
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
    Falchi L
    Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.